https://pubmed.ncbi.nlm.nih.gov/18286536/
The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role...
gemcitabinevinorelbinepemetrexedpatientsmalignant
https://www.cancerresearchuk.org/about-cancer/treatment/drugs/gemcitabine-nab-paclitaxel
Gemcitabine and nab-paclitaxel is a combination of chemotherapy drugs. It is a treatment for pancreatic cancer. Find out about how you have it, possible side...
information researchgemcitabinenabpaclitaxelcancer
https://www.mskcc.org/cancer-care/clinical-trials/20-348
Full Title A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR/Dexamethasone in Patients with Unresectable Intrahepatic...
phase ii studygemcitabineoxaliplatinchemotherapy
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1124912/full
Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabin...
smac mimeticfrontierscorrigendumcombininggemcitabine
https://www.gokkenroyale-online.fit/group-page/gokkenroyale-casino-group/discussion/1dcf014d-4bf7-486f-aa3d-39a791eaea6c
" In-Depth Study on Executive Summary Gemcitabine HCl Market Size and Share Global gemcitabine HCL market size was valued at USD 749.73 million in 2024 and is...
in depthexecutive summarystudygemcitabinehcl
https://www.mdpi.com/2072-6694/16/14/2561
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with...
as asequentialgemcitabinecabazitaxelintravenous
https://pubmed.ncbi.nlm.nih.gov/15238986/?utm_source=Firefox&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1jmC0p0kwOiCcoFdWNnDLt9teiWG5XXLdmSwZYr5NJoUy2Csb8&fc=20220328160043&ff=20220328160204&v=2.17.6
To compare irinotecan (CPT-11)+gemcitabine vs CPT-11 alone as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC) progressing...
the second lineirinotecanplusgemcitabinevs